We are a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through our acquisition of Lewis and Clark Pharmaceuticals Inc., we currently are focusing on a pipeline of small molecule adenosine receptor modulators.
Company profile
Ticker
RBSH, NSPXD
Exchange
Website
CEO
Christopher P. Lowe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENSPERA INC, Inspyr Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Inspyr Therapeutics, Inc. • Ridgeway Therapeutics, Inc. • Lewis and Clark Pharmaceuticals, Inc. ...
RBSH stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
21 Nov 22
8-K
Changes in Registrant's Certifying Accountant
16 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
8-K
Changes in Registrant's Certifying Accountant
13 Oct 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Latest ownership filings
SC 13G/A
SABBY MANAGEMENT, LLC
10 Jan 23
SC 13G/A
Inspyr Therapeutics, Inc.
21 Jan 20
SC 13G
Inspyr Therapeutics, Inc.
26 Nov 18
3
John Robison Montgomery
15 Aug 17
4
Bo Jesper Hansen
15 Aug 17
4
PETER E GREBOW
2 Aug 17
4
SCOTT VARDE OGILVIE
6 Mar 17
SC 13G/A
Inspyr Therapeutics, Inc.
9 Jan 17
4
Bo Jesper Hansen
28 Oct 16
3
Claire Thom
24 Oct 16
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bartlett & Co. | 2.00 | $0.00 |